FDA Clearance Tracker · P140032-S001
Remodulin
Last checked: Nov 20, 2026Latest source record: Jul 27, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Jul 27, 2018
Approved
Time to decision
186 days
Received Jan 22, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P140032-S001
- Device name
- Remodulin
- Applicant
- Medtronic, Inc.
- Applicant location
- Minneapolis, MN
- Received
- Jan 22, 2018
- Decided
- Jul 27, 2018
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P140032
Device type
- Device class
- Class III
- Specialty
- Hospital Medicine & Nursing
FDA's approval statement
As written in FDA's record.
Post-Approval Study protocol as a condition of approval for P140032 of the Medtronic Implantable System for Remodulin (ISR) for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P140032.
Source documents
Other decisions for Medtronic, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K263596 · Decided Oct 29, 2026 · 29 days after receipt
Device type: Catheter, Cannula And Tubing, Vascular, Cardiopulmonary Bypass (DWF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.